TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract
Recommended Citation
Wang X, Lopez-Beltran A, Osunkoya AO, Wang M, Zhang S, Davidson DD, Emerson RE, Williamson SR, Tan PH, Kaimakliotis HZ, Baldridge LA, MacLennan GT, Montironi R, and Cheng L. TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract. Future Oncol 2017.
Document Type
Article
Publication Date
4-1-2017
Publication Title
Future Oncol
Abstract
AIM: To determine TERT promoter mutation status as well as the expression of PAX8, GATA3, p63, p40, p53 and uroplakin III in 17 patients with the upper urinary tract sarcomatoid urothelial carcinoma.
METHODS & RESULTS: TERT C228T mutations were found in six of 17 cases (35%). p53 was expressed in 77% of these tumors. PAX8, GATA3, p40 and uroplakin III are less frequently expressed. Lymph node metastases were present in ten cases (59%). Eight patients (47%), including all three patients with TERT mutation, died of cancer within 2 years after surgery.
CONCLUSION: Sarcomatoid carcinoma of the upper urinary tract is an aggressive tumor and the presence of TERT mutation may portend poor prognosis.
Medical Subject Headings
Aged; Aged, 80 and over; Biomarkers; Carcinoma; Female; GATA3 Transcription Factor; Humans; Immunohistochemistry; Male; Middle Aged; Mutation; Neoplasm Staging; PAX8 Transcription Factor; Prognosis; Promoter Regions, Genetic; Telomerase; Tumor Suppressor Protein p53; Urethral Neoplasms; Urologic Neoplasms
PubMed ID
28052688
Volume
13
Issue
8
First Page
705
Last Page
714
